Hyperbaric versus Isobaric Bupivacaine for Spinal Anaesthesia:A Comparison of Block Quality and Haemodynamic StabilityA Systematic Review of Randomised Controlled Trials and Primary Studies

Abstract

Introduction: Bupivacaine remains the reference local anaesthetic for subarachnoid block, available in hyperbaric (glucose-containing) and isobaric (glucose-free) formulations. Baricity governs gravitational behaviour within cerebrospinal fluid (CSF), theoretically determining cephalad spread, block reliability, duration, and sympathectomy-mediated cardiovascular depression. However, contemporary practice remains divided, and no synthesis has simultaneously appraised block-quality and haemodynamic domains across diverse populations while incorporating discriminative analysis of baricity as a determinant of post-spinal hypotension. This review compared hyperbaric with isobaric bupivacaine across fourteen prespecified outcome domains encompassing block quality and haemodynamic stability.

Methods: The study strictly adhered to the Preferred Reporting Items for Systematic Review and Meta-Analysis (PRISMA) 2020 guidelines. Eligible designs included RCTs, cohort, case-control, cross-sectional, and other observational studies; systematic reviews and meta-analyses were excluded from characteristics tables and quantitative synthesis but retained for discussion. Risk of bias was appraised with Cochrane RoB 2 and Newcastle-Ottawa Scale. Dichotomous outcomes were pooled as risk ratios using DerSimonian-Laird random-effects models; heterogeneity was quantified with Q, I², and τ². An exploratory ROC analysis was constructed from reconstructed arm-level event data to quantify discriminative capacity of baricity for post-spinal hypotension. Certainty was graded using GRADE.

Results: Twenty studies (18 RCTs, 2 prospective observational; 1,281 participants) met eligibility criteria. Hyperbaric bupivacaine produced significantly faster motor block onset (pooled MD −4.6 min, 95% CI −7.5 to −1.7; p=0.002) and shorter time to T4 sensory level in obstetric setting (MD −1.06 min, 95% CI −1.80 to −0.31; p=0.005). Isobaric bupivacaine produced significantly longer sensory block (MD 29.4 min, 95% CI 15.5 to 43.3; p<0.001) and motor block (45.2 min, 95% CI 24.2 to 66.3; p<0.001). Block failure was significantly less frequent with hyperbaric formulation in paediatric trial (RR 0.22, 95% CI 0.05 to 0.98; p=0.047). The largest obstetric cohort demonstrated significantly lower hypotension (60% versus 82%; RR 0.73, 95% CI 0.56 to 0.95; p=0.015) and vasopressor requirement (14% versus 36%; RR 0.39, 95% CI 0.18 to 0.85; p=0.011) with hyperbaric bupivacaine. Pooled estimate for hypotension across three studies was RR 0.76 (95% CI 0.47 to 1.22; p=0.248; I²=49.7%). Exploratory ROC analysis yielded AUC 0.569 (95% CI 0.521 to 0.642), statistically distinguishable from chance yet indicating only weak discrimination. A monotonic baricity-spread gradient was demonstrated, mean maximum cephalad block rising from T9.5 with 0.33% glucose to T3.6 with 8% glucose. Risk of bias was low in 7 RCTs, some concerns in 8, high in 3; both observational studies scored 7/9 on NOS. GRADE certainty was moderate for block duration and motor onset, low for haemodynamic outcomes.

Discussion: Baricity exerts a reproducible and mechanistically coherent influence on the kinetics and geometry of subarachnoid drug distribution, but its translation into clinically important haemodynamic differences is modest and heavily conditioned by dose, patient position, CSF density, injection level, and, above all, vasopressor strategy. The divergence between significant obstetric cohort signal and neutral pooled estimate is best explained by lower CSF density of the parturient at term, rendering nominally isobaric solutions relatively hypobaric and promoting unpredictable cephalad migration. The discriminative analysis demonstrates that formulation choice explains only a marginal fraction of variance in post-spinal hypotension occurrence.

Conclusion: Hyperbaric bupivacaine confers faster, more predictable, and shorter block; isobaric bupivacaine confers longer block with slower and less predictable onset. Neither formulation is universally superior for haemodynamic stability, although hyperbaric bupivacaine is preferable where block predictability is paramount, most notably in obstetric practice. Formulation choice should be dictated by required block level and duration, patient positioning, and population-specific CSF density rather than by assumption of intrinsic cardiovascular superiority.